MFS Equity Income Fund Class R3 (EQNTX)
NASDAQ · Mutual Fund
· Delayed Price · Currency is USD
21.96
+0.05 (0.23%)
Jun 9, 2025, 4:00 PM EDT
2.47% (1Y)
Fund Assets | 203.85M |
Expense Ratio | 0.89% |
Min. Investment | $0.00 |
Turnover | n/a |
Dividend (ttm) | 1.30 |
Dividend Yield | 5.93% |
Dividend Growth | 67.62% |
Payout Frequency | Quarterly |
Ex-Dividend Date | Mar 25, 2025 |
Previous Close | 21.91 |
YTD Return | 4.67% |
1-Year Return | 8.40% |
5-Year Return | 84.12% |
52-Week Low | 18.52 |
52-Week High | 23.13 |
Beta (5Y) | n/a |
Holdings | 101 |
Inception Date | Sep 27, 2012 |
About EQNTX
EQNTX was founded on 2012-09-27. The Fund's investment strategy focuses on Equity Income with 0.89% total expense ratio. MFS Series Trust VII: MFS Equity Income Fund; Class R3 Shares seeks total return through a combination of current income and capital appreciation. EQNTX normally invests at least 80% of the funds net assets in equity securities. MFS invests the majority of the funds assets in dividend-paying common stocks, but may invest in other types of income-producing securities.
Category Large Value
Stock Exchange NASDAQ
Ticker Symbol EQNTX
Share Class R3
Performance
EQNTX had a total return of 8.40% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.93%.
Top 10 Holdings
22.05% of assetsName | Symbol | Weight |
---|---|---|
Wells Fargo & Company | WFC | 2.98% |
AbbVie Inc. | ABBV | 2.57% |
JPMorgan Chase & Co. | JPM | 2.47% |
The Cigna Group | CI | 2.40% |
Pfizer Inc. | PFE | 2.10% |
QUALCOMM Incorporated | QCOM | 2.02% |
Alphabet Inc. | GOOGL | 2.00% |
McKesson Corporation | MCK | 1.88% |
The Home Depot, Inc. | HD | 1.81% |
Ameriprise Financial, Inc. | AMP | 1.80% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Mar 25, 2025 | $0.05919 | Mar 26, 2025 |
Dec 12, 2024 | $1.02341 | Dec 13, 2024 |
Sep 26, 2024 | $0.10043 | Sep 27, 2024 |
Jun 25, 2024 | $0.11564 | Jun 26, 2024 |
Mar 26, 2024 | $0.08809 | Mar 27, 2024 |
Dec 14, 2023 | $0.51045 | Dec 15, 2023 |